Using a validated RNA-based signature of NRF2 signalling, we further demonstrate that higher baseline levels of NRF2 signalling contribute to a radioresistant phenotype in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Here, NFE2L2 is linked to rectal cancer.